Trial Profile
Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms EMBRACE-HF
- 10 Nov 2021 Status changed from active, no longer recruiting to completed.
- 18 Mar 2021 Planned End Date changed from 30 Jan 2021 to 30 Apr 2021.
- 08 Feb 2021 Primary endpoint has been met. (To compare the change in pulmonary artery diastolic pressure from baseline to end of treatment period between empagliflozin and placebo), as per Results published in the Circulation